Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bladder disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    473 result(s) found for: Bladder disease. Displaying page 3 of 24.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-018246-38 Sponsor Protocol Number: Jun_11_2009_Updated_Nov_2009 Start Date*: 2010-12-23
    Sponsor Name:Antoni van Leeuwenhoek Ziekenhuis
    Full Title: Phase II trial evaluating combined image guided radiotherapy with Panitumumab (Vectibix®) in patients with muscle invasive transitional cell carcinoma of the bladder
    Medical condition: patients with muscle invasive transitional cell carcinoma of the bladder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10005017 Bladder carcinoma stage 0, with cancer in situ LLT
    12.1 10005019 Bladder carcinoma stage I, with cancer in situ LLT
    12.1 10005021 Bladder carcinoma stage II LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005095-18 Sponsor Protocol Number: ICR-CTSU/2013/10041 Start Date*: 2014-09-19
    Sponsor Name:The Institute of Cancer Research
    Full Title: A phase II randomised feasibility study of chemoresection and surgical management in low risk non muscle invasive bladder cancer.
    Medical condition: Low risk non muscle invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-003842-18 Sponsor Protocol Number: A301223 Start Date*: 2014-04-24
    Sponsor Name:Erasmus MC
    Full Title: Prevention of renal and bladder damage in children with spina bifida by means of early injections with Botulinum-Toxin-A (Botox): a pilot study.
    Medical condition: Neurogenic bladder function disease in spina bifida patients.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10030685 Open spina bifida LLT
    16.1 100000004850 10041531 Spina bifida without mention of hydrocephalus LLT
    16.1 100000004857 10029280 Neurogenic bladder, not otherwise specified LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001826-28 Sponsor Protocol Number: BL-2007-02 Start Date*: 2007-11-28
    Sponsor Name:Queen Mary University London
    Full Title: A phase II/III, randomised, two-arm comparison of maintenance lapatinib versus placebo after firrst-line chemotherapy in patients with HER1 and/or HER2 over expressing locally advanced or metastati...
    Medical condition: The medical condition being investigated in this trial is locally advanced or metastatic urological cancer. The tumour must overexpress HER1 and/or HER2 gene.
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005012 Bladder cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002765-22 Sponsor Protocol Number: SOGUG-2017-A-IEC(VEJ)-2/NEODURVARIB Start Date*: 2018-09-04
    Sponsor Name:Spanish Oncology Genitourinary Group - SOGUG
    Full Title: Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer
    Medical condition: Resectable urothelial bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000192-42 Sponsor Protocol Number: 191622-516 Start Date*: 2007-07-25
    Sponsor Name:Allergan Ltd
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment with Two Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified N...
    Medical condition: Urinary incontinence due to neurogenic detrusor overactivity
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029279 Neurogenic bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed) PT (Completed) ES (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-007053-13 Sponsor Protocol Number: STEG-CORP_111802 Start Date*: 2009-07-31
    Sponsor Name:Grachtenhaus-Apotheke, Inh. Klaus Stegemann e. K.
    Full Title: Doppelblinde, randomisierte, Placebo-kontrollierte Studie der Phase III zur Bestimmung der Wirksamkeit, Verträglichkeit und Sicherheit von intravesikal verabreichter Oxybutynin-Lösung bei Kindern/J...
    Medical condition: bladder disorder (detrusor hyperactivity caused by neurogenic disorder)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061011 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-001823-38 Sponsor Protocol Number: AB65/18 Start Date*: 2018-11-26
    Sponsor Name:Technische Universität München, Fakultät für Medizin vertreten durch den Dekan
    Full Title: A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urot...
    Medical condition: Locally advanced urothelial bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002676-40 Sponsor Protocol Number: CA045-009 Start Date*: 2019-07-03
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus Bempegaldesleukin (NKTR-214), Versus Nivolumab Alone Versus Standard of Care in Participants with Muscle-Invasive Bladder Can...
    Medical condition: Muscle-Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) AT (Completed) GR (Completed) ES (Ongoing) CZ (Completed) PL (Completed) FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002100-13 Sponsor Protocol Number: ESR-16-12611 Start Date*: 2018-10-11
    Sponsor Name:Hellenic GenitoUrinaty Cancer Group (HGUCG)
    Full Title: Intravesical administration of Durvalumab (MEDI4736) to patients with high-risk, non-muscle-invasive bladder cancer (NMIBC). A phase II study with correlative biomarker studies.
    Medical condition: Non-muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002826-55 Sponsor Protocol Number: SECAVIN-12 Start Date*: 2012-10-17
    Sponsor Name:Associació Per a la Recerca Oncològica (APRO)
    Full Title: A randomised Phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium
    Medical condition: metastatic or locally advanced transitional cell carcinoma of the urothelium
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005084 Bladder transitional cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003813-92 Sponsor Protocol Number: EPT02/2016 Start Date*: 2017-01-25
    Sponsor Name:IBSA FARMACEUTICI ITALIA SRL
    Full Title: Open clinical trial to evaluate the efficacy of intravesical instillation of hyaluronate added to early instillation of mitomycin vs early instillation of mitomycin in patients suffering from low r...
    Medical condition: Low risk not muscle-infiltrating bladder neoplasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005005 Bladder cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001268-57 Sponsor Protocol Number: 905-CL-058 Start Date*: 2007-09-12
    Sponsor Name:Astellas Pharma US, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate with 0.4 mg Tamsulosin Hydrochlo...
    Medical condition: Storage and Voiding Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027561 Micturition disorder LLT
    9.1 10005053 Bladder neck obstruction LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021265-80 Sponsor Protocol Number: PHRCNATHorsCancer2010-HC11-05 Start Date*: 2010-10-18
    Sponsor Name:Centre Hospitalier Universitaire de Reims
    Full Title: Injections intradétrusoriennes de toxine botulique A chez l'enfant présentant un syndrome d'hyperactivité vésicale neurogène : essai thérapeutique contrôlé multicentrique de non infériorité entre d...
    Medical condition: Syndrome d'hyperactivité vésicale neurogène chez l'enfant
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029279 Neurogenic bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021241-44 Sponsor Protocol Number: PHRI06 – LB / PACHIU Start Date*: 2010-12-13
    Sponsor Name:CHRU de TOURS
    Full Title: Etude multicentrique, randomisée en groupes parallèles, évaluant l’efficacité et la tolérance d’un antibiocycle hebdomadaire dans la prévention des infections urinaires sur vessie neurologique.
    Medical condition: troubles de la vessie dû à une maladie neurologique
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029279 Neurogenic bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023406-13 Sponsor Protocol Number: DZITM1 Start Date*: 2011-03-18
    Sponsor Name:Städtische Kliniken Neuss, Lukaskrankenhaus GmbH
    Full Title: Target-spezifische Therapie mit Pazopanib zusätzlich zu Vinflunin bei Patienten mit fortgeschrittenem oder metastasiertem Urothelkarzinom nach Versagen einer platinhaltigen Therapie
    Medical condition: Advanced urothelial carcinoma of the bladder
    Disease: Version SOC Term Classification Code Term Level
    12.1 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006935-38 Sponsor Protocol Number: A0221008 Start Date*: 2007-04-16
    Sponsor Name:Pfizer Inc. NYO-685-21-14,685 3rd Avenue, NEW YORK, NY 10017. US
    Full Title: 12-WEEK, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FESOTERODINE IN COMPARISON TO TOLTERODINE ER IN PATIENT...
    Medical condition: Treatment of overactive bladder with symptoms of frequency, urgency, and urgency incontinence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) BE (Completed) HU (Completed) DK (Completed) CZ (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004844-27 Sponsor Protocol Number: SURE-01 Start Date*: 2021-06-01
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: SURE-01_An open label, single-arm, phase 2 study of neoadjuvant sacituzumab govitecan, before radical cystectomy, for patients with muscle-invasive bladder cancer who cannot receive or refuse cispl...
    Medical condition: Muscle-invasive bladder cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10007293 Carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002361-39 Sponsor Protocol Number: BAY 79-4998 / 12331 Start Date*: 2006-12-01
    Sponsor Name:Bayer Vital GmbH
    Full Title: A 4-week, open-label, multicenter, urodynamic pilot study to explore the efficacy, tolerability and safety of darifenacin (7.5 mg with up-titration to 15 mg) in patients with multiple sclerosis and...
    Medical condition: Neurogenic overactive bladder disaese in patients with multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000905-19 Sponsor Protocol Number: Rec0/0438-IT-CL0491 Start Date*: 2018-01-29
    Sponsor Name:Recordati S.p.A
    Full Title: EFFECTS OF TWO DIFFERENT DOSES OF REC 0/0438 ADMINISTERED BY INTRA-VESICAL INSTILLATION IN PATIENTS WITH NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY: A REPEATED DOSES, DOUBLE-BLIND,...
    Medical condition: neurogenic detrusor overactivity due to spinal cord injury
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10005059 Bladder neurogenic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed) PL (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 07:48:20 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA